脂质代谢异常在糖尿病肾脏病发病中的作用
摘要
随着人口老龄化和生活方式改变，2型糖尿病（type 2 diabetes mellitus，T2DM）的发病率逐年升高，其中25％-40％的患者出现糖尿病肾脏病（diabetic kidney disease，DKD）^[1]。在欧美等发达国家以及台湾地区，DKD的发病率居继发性肾小球疾病的首位，是终末期肾脏病（ESRD）行肾脏替代治疗的主要原因。
出处
《临床肾脏病杂志》
2009年第10期286-287,共2页
Journal Of Clinical Nephrology
参考文献16
-
1Amanda I. Adler, Riachard J. Stevens, Sue E. Manley,et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS64). Kidney International, 2003,63,225- 232.
-
2Xie YX, Chen XM. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am J Nephrol,2008,28:1- 7.
-
3Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med, 1998,158:998- 1004.
-
4Taskinen MR. Diabetic dyslipidemia. Atheroscler, 2002, Suppl 3: 47 -51.
-
5Santini E, Lupi R, Baldi S, et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia,2008,51,2117-2125.
-
6Li J, Li H,Wen YB, et al. Very-low-density lipoprotein-induee triglyceride accumultion in human mesangial cell mediated by lipoprotein lipase. Nephron Physiol, 2008,110,1-10.
-
7Nakamura T, Kawague Y, Oqawa H, et al. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patient with nephritic syndrome due to diabetic nephropathy. Am J Kidney Dis, 2005,45 : 48-53.
-
8Paul Gutwein, Mohamed Sadek, Anja Schramme, et al. CXCL16 is expressed in podocyte and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J pathol, 21109,174,2061-72.
-
9Sakamoto N, Ishibashi T, Suqimoto K, et al. Role of LOX-I in monocyte adhesion-triggered redox, Akt/eNOS and Ca2+ signaling pathways in endothelial cell. J Cell Physiol, 2009,220,706- 715.
-
10Susztak K, Ciccone E, Mccue P, et al. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. Plos Medicine, 2005,2,152 161.
-
1苗里宁,远航.狼疮性肾炎免疫抑制剂治疗的选择[J].临床肾脏病杂志,2009,9(2):52-55. 被引量：3
-
2高丽,王新婷,叶新华.环磷酰胺治疗狼疮性肾炎的护理观察[J].护理研究（下旬版）,2007,21(3):790-791. 被引量：12
-
3曹思,吴小燕.糖尿病肾脏病肾小管损伤研究进展[J].临床肾脏病杂志,2015,15(3):185-188. 被引量：3
-
4黄云剑,王梓华.狼疮性肾炎的药物治疗进展[J].中国医师进修杂志,2009,32(4):70-72. 被引量：1
-
5翁小斌,鲍金芳.过敏性紫癜患儿血清IL-6、IL-12、TFN-α水平变化及临床意义[J].浙江医学,2014,36(9):791-792. 被引量：7
-
6舒芬华,林丽.狼疮性肾炎患儿护理进展[J].护理实践与研究,2011,8(20):101-103.
-
7李亚妤,叶彬.肾穿刺活检1171例临床病理分析[J].杭州医学高等专科学校学报,2003,24(5):236-237. 被引量：5
-
8黄元庆.基层医院在糖尿病肾脏疾病临床诊断中需注意的问题[J].中国煤炭工业医学杂志,2010,13(9):1427-1427.
-
9马璋如.糖尿病肾脏病的治疗现状[J].临床荟萃,1999,14(24):1142-1143. 被引量：2
-
10王刚,梁东,刘华锋.乙型肝炎病毒相关性肾炎的诊疗进展[J].医学综述,2012,18(11):1695-1697. 被引量：1
